Niagen Bioscience (NAGE) Price & Analysis

Compare

624 Followers

NAGE Stock Chart & Stats

$6.31

Market closed

$6.31

Day’s Range― - ―

52-Week Range$5.25 - $14.69

Previous CloseN/A

VolumeN/A

Average Volume (3M)761.48K

Market Cap

$503.58M

Enterprise Value$746.92M

Total Cash (Recent Filing)$64.14M

Total Debt (Recent Filing)$3.06M

Price to Earnings (P/E)25.4

Beta0.90

Next Earnings

Mar 11, 2026

EPS Estimate

0.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.05

Shares Outstanding79,806,140

10 Day Avg. Volume830,460

30 Day Avg. Volume761,479

Financial Highlights & Ratios

PEG Ratio-0.22

Price to Book (P/B)9.84

Price to Sales (P/S)4.55

P/FCF Ratio37.97

Enterprise Value/Market Cap1.48

Enterprise Value/Revenue5.99

Enterprise Value/Gross Profit9.37

Enterprise Value/Ebitda35.33

Forecast

1Y Price Target

$16.33

Price Target Upside158.80% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)0.3

Revenue Forecast (FY)$153.23M

Bulls Say, Bears Say

Bulls Say

Intellectual PropertyAcquisition of additional nicotinamide riboside patents strengthens proprietary protections around TruNiagen, reducing competitive risk and supporting potential pricing power.

Product DifferentiationProprietary nicotinamide riboside formulation is positioned as more effective at raising NAD+ than alternative formats, which can drive consumer preference and support premium positioning.

Product ExpansionLaunch of Tru Niagen Beauty in the US expands the brand into the internal beauty category, increasing the target market and creating new retail and e-commerce growth opportunities.

Bears Say

Clinical Trial ResultsA study failed to show statistically significant improvement for long COVID symptoms after five weeks of supplementation, introducing uncertainty around short-term therapeutic claims.

Niagen Bioscience News

Niagen Bioscience partners with Truemed for pre-tax health payments

Niagen Bioscience (NAGE) announced it has partnered with Truemed to allow qualified customers to purchase Tru Niagen using...

3d ago

NAGE

Niagen Bioscience acquires existing nicotinamide riboside patent portfolio

Niagen Bioscience (NAGE) announced that it has acquired a portfolio of existing patents covering nicotinamide riboside and its...

27d ago

NAGE

Niagen Bioscience: Strengthened NR Patent Control and Differentiated Efficacy Support Buy Rating and $14 Target

Niagen Bioscience, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Susan Anderson from...

25d ago

NAGE

Niagen Bioscience Secures Full Ownership of Key NR Patents

Niagen Bioscience ( ($NAGE) ) has shared an update. On December 16, 2025, Niagen Bioscience’s subsidiary ChromaDex, Inc....

27d ago

NAGE

Niagen Bioscience management to meet with Roth Capital

Meeting to be held in Chicago on December 3 hosted by Roth Capital. Published first on TheFly –...

2M ago

NAGE

Niagen Bioscience announces results of Niagen supplementation in long COVID

Niagen Bioscience (NAGE) shared promising results from the first-of-its-kind clinical trial published today in The Lancet peer-reviewed journal...

2M ago

NAGE

Niagen Bioscience announces $10M share repurchase program

Niagen Bioscience (NAGE) announced that its board of directors has approved a share repurchase program under which the...

2M ago

NAGE

Niagen Bioscience Announces $10 Million Share Buyback

Niagen Bioscience ( ($NAGE) ) has provided an announcement. On November 6, 2025, Niagen Bioscience announced that its...

2M ago

NAGE

ChromaDex Reports Record Growth Amid Strategic Expansions

ChromaDex Corporation (($NAGE)) has held its Q3 earnings call. Read on for the main highlights of the call....

2M ago

NAGE

Niagen Bioscience price target lowered to $14 from $16 at Canaccord

Canaccord lowered the firm’s price target on Niagen Bioscience (NAGE) to $14 from $16 and keeps a Buy...

2M ago

NAGE

Niagen Bioscience Reports Strong Q3 2025 Results

ChromaDex Corporation ( ($NAGE) ) has released its Q3 earnings. Here is a breakdown of the information ChromaDex...

2M ago

NAGE

Niagen Bioscience Reports 33% Q3 Sales Increase

Niagen Bioscience ( ($NAGE) ) has issued an announcement. On November 4, 2025, Niagen Bioscience reported a 33%...

2M ago

NAGE

Niagen Bioscience reports Q3 EPS 5c vs 2c last year

Reports Q3 revenue $33.986M, consensus $31.1M. “We delivered another strong performance with third quarter net sales of $34.0...

2M ago

NAGE

Niagen Bioscience reiterates FY25 net sales growth view of 25%-30%

For the full year, the Company reiterated its recently revised top-line guidance of 25% to 30% year-over-year net...

2M ago

NAGE

NAGE FAQ

What was Niagen Bioscience’s price range in the past 12 months?

Niagen Bioscience lowest stock price was $5.25 and its highest was $14.69 in the past 12 months.

What is Niagen Bioscience’s market cap?

Niagen Bioscience’s market cap is $503.58M.

When is Niagen Bioscience’s upcoming earnings report date?

Niagen Bioscience’s upcoming earnings report date is Mar 11, 2026 which is in 52 days.

How were Niagen Bioscience’s earnings last quarter?

Niagen Bioscience released its earnings results on Nov 04, 2025. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.018 by $0.032.

Is Niagen Bioscience overvalued?

According to Wall Street analysts Niagen Bioscience’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Niagen Bioscience pay dividends?

Niagen Bioscience does not currently pay dividends.

What is Niagen Bioscience’s EPS estimate?

Niagen Bioscience’s EPS estimate is 0.02.

How many shares outstanding does Niagen Bioscience have?

Niagen Bioscience has 79,806,140 shares outstanding.

What happened to Niagen Bioscience’s price movement after its last earnings report?

Niagen Bioscience reported an EPS of $0.05 in its last earnings report, beating expectations of $0.018. Following the earnings report the stock price went down -1.007%.

Which hedge fund is a major shareholder of Niagen Bioscience?

Currently, no hedge funds are holding shares in NAGE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Niagen Bioscience Stock Smart Score

Outperform

Fundamentals

Return on Equity

38.90%

Trailing 12-Months

Asset Growth

73.63%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Niagen Bioscience

Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.

Niagen Bioscience (NAGE) Earnings & Revenues

Historic Earnings Reports

NAGE Company Deck

NAGE Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented a strong performance with record revenue growth and strategic expansions. However, challenges remain in regulatory environments and pricing strategies in certain markets.View all NAGE earnings summaries

NAGE Stock 12 Month Forecast

Average Price Target

$16.33

▲(158.80% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","14":"$14","19":"$19","24":"$24"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$23.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,9,14,19,24],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.67,7.926153846153846,9.182307692307692,10.438461538461539,11.694615384615384,12.950769230769229,14.206923076923076,15.46307692307692,16.71923076923077,17.975384615384613,19.23153846153846,20.487692307692306,21.74384615384615,{"y":23,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.67,7.413076923076923,8.156153846153845,8.899230769230769,9.642307692307693,10.385384615384615,11.128461538461538,11.87153846153846,12.614615384615384,13.357692307692307,14.10076923076923,14.843846153846153,15.586923076923076,{"y":16.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.67,7.08,7.49,7.9,8.31,8.72,9.129999999999999,9.54,9.95,10.36,10.77,11.18,11.59,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.86,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.64,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.87,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.81,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.88,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.89,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.54,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.67,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >